Securities code: 600436 securities abbreviation: Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) Announcement No.: 2022-007 Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436)
Announcement on 2021 annual performance express
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
The main financial data for 2021 contained in this announcement is the preliminary accounting data of Zhangzhou Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) Pharmaceutical Co., Ltd. (hereinafter referred to as “the company”), which has not been audited by an accounting firm. The specific financial data of 2021 annual performance shall be subject to the data disclosed in the company’s 2021 annual report.
Please make careful decisions and pay attention to investment risks.
1、 Main financial data and indicators in 2021
Unit: RMB 10000
Increase / decrease items in the same period of last year in the current reporting period
Range (%)
Total operating income 802584.54 651078.20 23.27
Operating profit 289699.76 197708.95 46.53
Total profit 288907.21 197889.83 45.99
Attributable to listed companies
243297.53 167151.87 45.55 the net profit of shareholders belongs to the shareholders of the listed company
Net profit after deducting non recurring profit and loss 243028.52 158912.89 52.93
Increase or decrease
The current reporting period of the project is the same period of last year
Range (%)
Basic earnings per share (yuan) 4.03 2.77 45.49
Weighted average increase of 4.53 27.60 23.07
Percentage point of return on net assets
Increase or decrease
At the end of the reporting period and at the beginning of the reporting period
Range (%)
Total assets 1257308.65 1020556.97 23.20
Attributable to listed companies
976686.33 786217.00 24.23 owner’s equity of shareholders
Share capital 60331.72 60331.72-
Attributable to shareholders of listed companies
16.19 net assets per share (yuan) of 13.03 24.25 note: 1. The beginning amount of this report is the same as the end amount of the previous year legally disclosed.
2. The report period is filled in with unaudited consolidated statement data.
2、 Description of operating performance and financial position
1. The company’s total operating revenue increased by 23.27% year-on-year, mainly due to the strengthening of market planning and expansion of sales channels, and the increase in sales revenue of the company, its holding subsidiary Xiamen Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) Hongren Pharmaceutical Co., Ltd. (merger) and its holding subsidiary Fujian Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) Cosmetics Co., Ltd. (merger).
2. The company’s operating profit increased by 46.53%, total profit increased by 45.99%, net profit attributable to shareholders of listed companies increased by 45.55%, net profit attributable to shareholders of listed companies net of non recurring profits and losses increased by 52.93% and basic earnings per share increased by 45.49% year-on-year, mainly due to the company’s expansion of marketing channels, The new online Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) pharmacy tmall flagship store and Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) pharmacy Jingdong flagship store increased profits.
3、 Risk tips
The above main financial data for 2021 is the company’s preliminary accounting data, which has not been audited by an accounting firm. The specific financial data of 2021 annual performance shall be subject to the data disclosed in the company’s 2021 annual report.
Please make careful decisions and pay attention to investment risks.
4、 Online announcement attachment
Comparative balance sheet and income statement signed and sealed by the current legal representative, chief accountant and head of accounting institution of the company.
It is hereby announced.
Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) board of directors
January 20, 2022
